by David Wallace The Big Picture If you’ve been diagnosed with a myeloproliferative neoplasm (MPN) such as polycythemia vera, essential thrombocythemia, or myelofibrosis, you’ve likely heard about interferon therapy. Keep reading to discover what current research tells us about this treatment option. What Exactly Is Interferon? Think of interferon as your body’s natural antiviral security […]
Beta-Alanine for PV Related Itching: A Potential Solution
by David Wallace For many people living with polycythemia vera (PV) and other myeloproliferative neoplasms, stepping into a warm shower can trigger an unbearable sensation that has nothing to do with the water temperature. Aquagenic pruritus (intense itching that occurs after contact with water) remains one of the most frustrating symptoms patients face, affecting nearly […]
Polycythemia Vera Brain Fog
by David Wallace updated July 10, 2025 This is no wonderful “epiphany moment” article, just a quick report on a real myeloproliferative neoplasm (MPN) symptom I experience from time to time. Many mornings, I make a healthy smoothie to get me up and rolling. This morning I grabbed the wrong ingredient and sprinkled it in […]
Breakthrough CALR Therapy Shows High Response Rate in ET
by David Wallace New Treatment Targets Root Cause of ET: INCA033989 Trial Shows Powerful Results June 15, 2025 – EHA Congress, Milan Incyte has announced positive, late-breaking data from the first clinical studies of its experimental therapy INCA033989—an antibody designed to precisely target a genetic driver of disease in patients with Essential Thrombocythemia (ET). The […]
Rusfertide Cuts Phlebotomies by 77% in Polycythemia Vera
by David Wallace Key Points Rusfertide achieved clinical response in 77% of patients compared to 33% with placebo in the Phase 3 VERIFY trial The drug significantly reduced the number of blood draws needed each year and decreased PV-related symptoms Rusfertide maintained hematocrit levels below 45% and reduced or eliminated the need for phlebotomy Safety […]
